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Human Diseases from Gain-of-Function Mutations in Disordered Protein Regions
Xiao-Han Li 1, * and M. Madan Babu 1, * Although there is much focus on the impact of mutations on structured protein domains, less is known about their impact on unstructured regions. In this issue, Meyer et al. demonstrate that mutations resulting in the emergence of new short linear peptide motifs within intrinsically disordered protein regions can cause human genetic diseases by gain of function.
Single-nucleotide changes in genomic loci are a common source of human genetic diseases. Missense mutations within protein-coding regions often cause disease by the loss of protein function, for instance, by disrupting critical protein interactions (Sahni et al., 2015) . Although most disease mutations have been documented to occur in functional sites within structured protein domains, 20% of disease mutations occur within intrinsically disordered regions (IDRs) (Vacic et al., 2012) . IDRs are polypeptide segments that do not fold into a stable tertiary structure and often act as critical hubs in protein interaction networks (van der Lee et al., 2014) . IDRs frequently mediate protein interactions through short linear motifs (SLiMs), which are stretches of 2-10 amino acids, and can be regulated by post-translational modifications (PTMs) (Tompa et al., 2014) . Not surprisingly, disease-causing mutations in IDRs affect SLiMs or PTM sites and disrupt protein interactions (Vacic et al., 2012) .
The fact that disordered regions can mediate diverse interactions adds an important missing piece to our understanding of the mechanism of protein function and disease mutations. Now, Meyer et al. (2018, this issue of Cell) use a proteomics screening approach to discover new SLiMs that emerge as a result of disease-related mutations (Meyer et al., 2018) . They find that gain of a new dileucine motif (i.e., the presence of two leucine residues next to each other) in cytosolic IDRs of transmembrane proteins leads to increased clathrin binding. This results in abnormal phenotypes due to mislocalization of the receptor through clathrin-dependent trafficking. These findings illustrate the importance of IDRs in disease manifestation through a gain-of-function mechanism ( Figure 1A) . Meyer et al. (2018) first identify 128 candidate sequences with a length of 15 amino acids by a combination of mutation database search, disorder prediction, and disease classification. For each candidate, the authors synthesize and test a pair of wild-type/mutant peptides in vitro for protein interactions using shotgun proteomics techniques. A mutation is considered a positive hit if the mutant peptide shows significant enrichment of new interaction partners compared to the wild-type peptide. The screening reveals that neurological disease mutations in the cytosolic IDRs of three transmembrane proteins (glucose transporter 1, GLUT1; intracellular IP3-gated calcium channel, ITPR1, and the voltage-gated calcium channel, CACNA1H) could increase clathrin binding. The mutations are all involved in the emergence of a new dileucine motif, which has been previously reported to recruit clathrin in the cytoplasmic region.
A detailed investigation using GLUT1 receptor as a model shows that the dileucine motif alters the localization of the receptor from the plasma membrane, where it can mediate glucose transport, to intracellular compartments by interacting with vesicular transport adaptor proteins AP-1, AP-2, and AP-3. Mislocalization caused by this gain of function results in a reduced abundance of GLUT1 in the plasma membrane ( Figure 1B) . This leads to glucose-transport deficiency in cells and makes the corresponding mutation pathogenic. Intriguingly, further analysis of disease mutation databases reveals a total of 11 instances of a gain of dileucine motif in 8 different transmembrane proteins that are implicated in a wide range of diseases ( Figure 1B) . Thus, gain of function through the emergence of a dileucine motif, specifically in the IDRs of cytosolic regions of membrane proteins, could cause mistrafficking and may serve as a shared molecular mechanism among diverse diseases involving membrane proteins.
This proteomics-based technique takes advantage of the short length of SLiMs and demonstrates an experimental design strategy in terms of bottom-up screening. The combination of in silico computational pre-screening and state-of-the-art shotgun proteomics opens the door to the identification of SLiMs that can confer new functions. However, with only 128 sequences being screened, the throughput of this approach is still orders of magnitude below the scale of genomic screening approaches. Another limitation of the technique is that it relies on an in vitro approach to detect binding partners. This may not always capture the physiologically relevant interactions that require specific spatiotemporal contexts and full-length proteins.
How can one discover functional SLiMs within disordered regions on a genomic scale to provide insight into molecular mechanisms of biological processes and pathogenesis? Recent developments in phage display (Davey et al., 2017) , proximity labeling (Minde et al., 2018) , saturation mutagenesis (Staller et al., 2018) , ligand foot-printing mass spectrometry (Parker et al., 2018) , and innovative screening approaches such as IDR-screen (Ravarani et al., 2018) are beginning to provide genome-scale characterization of motifs within IDRs and the functions associated with them. The IDR-screen approach allows investigating the effect of mutations in cancer genomes and natural variation in the human population in a cellular context. Thus, scaling up the current pipeline of this study or combining this design with other in cell screening approaches might be a future direction to accelerate the discovery of gain-of-function mutations in IDRs.
How commonly do mutations within IDRs result in gain of function and thereby cause disease? In contrast to structured domains, the sequences of IDRs are known to change more rapidly across species during evolution. Moreover, since the protein interactions mediated by SLiMs within IDRs are less complex compared to the fine-tuned interfaces between structured protein domains, new protein interactions can emerge or disappear rapidly with just a few mutations (Tompa et al., 2014) . In other words, a small number of mutations within disordered regions have a high potential to form new connections or disrupt existing ones. This also means that random mutations within IDRs are more likely to cause diseases via a gain-of-function mechanism compared to structured domains. While it is still hard to evaluate how detrimental this evolutionary flexibility could be, with the discovery and deeper understanding of SLiMs and their function, we should be able to get a better view of genetic diseases from a molecular, mechanistic, and systems-level perspective.
